Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions

In recent years, there have been significant breakthroughs in the identification of immunological components of skin diseases and in the development of immunomodulatory drugs. Novel therapies create exciting prospects for personalized care. This article provides an overview of the role played by Th1...

Full description

Saved in:
Bibliographic Details
Published in:Immune network 2024, 24(5), , pp.1-21
Main Authors: Speeckaert, Reinhart, Belpaire, Arno, Lambert, Jo, Speeckaert, Marijn, van Geel, Nanja
Format: Article
Language:English
Subjects:
Review
면역학
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2563-863e6e203a15f32d44805776e3d3c8e1b1ce75efa9ba99262070933e377cc403
container_end_page 21
container_issue 5
container_start_page 1
container_title Immune network
container_volume 24
creator Speeckaert, Reinhart
Belpaire, Arno
Lambert, Jo
Speeckaert, Marijn
van Geel, Nanja
description In recent years, there have been significant breakthroughs in the identification of immunological components of skin diseases and in the development of immunomodulatory drugs. Novel therapies create exciting prospects for personalized care. This article provides an overview of the role played by Th1, Th2, Th17, and follicular Th pathways in the most common skin diseases. Additionally, it elucidates the impact of current and upcoming treatments on each of these signaling cascades. Skin diseases predominantly influenced by a single dominant Th pathway such as psoriasis and atopic dermatitis are well-suited for biologics. However, in many other disorders a complex interplay between different immune pathways exists. This can lead to inconsistent efficacy of biologics based on individual patient profiles. In case of activation of several Th pathways, it may be more suitable to consider conventional therapies or JAK inhibitors. Increasing immunological insights have transitioned from laboratory research to practical applications, a trend that is expected to continue growing in the future.
doi_str_mv 10.4110/in.2024.24.e33
format article
fullrecord <record><control><sourceid>nurimedia_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10643179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><nurid>NODE11958682</nurid><sourcerecordid>NODE11958682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2563-863e6e203a15f32d44805776e3d3c8e1b1ce75efa9ba99262070933e377cc403</originalsourceid><addsrcrecordid>eNpVkc1vEzEQxS0EomnhyhH5goSQNvhj7bW5oKgpJVKhiO6Bm-V4ZxuTrLfYu0X97_E2IQJppJE8v3mep4fQK0rmJaXkvQ9zRlg5zwWcP0EzRjQrpFTiKZpRoVXBJNMn6DSln4TIklfiOTrhWlBOmJ6hH_UGf7PD5rd9SNgHvOq6MUDxBRpvB2jwzTY_Ln3qYwMxfcALfDn6BnDbR3wzxMzceofrCHboIAx4Cc4n34f0Aj1r7S7By0M_Q_Wni_r8c3F1fbk6X1wVjgnJCyU5SGCEWypazpqyVERUlQTecKeArqmDSkBr9dpqnb2QimjOgVeVcyXhZ-jdXjbE1mydN731j_22N9toFt_rlaGTb1rpDH_cw3fjuoPG5YOj3Zm76DsbHx5X_58Ev8lC94ZSwZUkk8Lbg0Lsf42QBtP55GC3swH6MRlOmeKM6VJldL5HXexTitAe_6HETNkZH8yUncmVs8sLr_-97oj_DSsDbw5exzyaEjoyX6-XF5RqoaRi_A9BUaBY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128322948</pqid></control><display><type>article</type><title>Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions</title><source>Open Access: PubMed Central</source><creator>Speeckaert, Reinhart ; Belpaire, Arno ; Lambert, Jo ; Speeckaert, Marijn ; van Geel, Nanja</creator><creatorcontrib>Speeckaert, Reinhart ; Belpaire, Arno ; Lambert, Jo ; Speeckaert, Marijn ; van Geel, Nanja</creatorcontrib><description>In recent years, there have been significant breakthroughs in the identification of immunological components of skin diseases and in the development of immunomodulatory drugs. Novel therapies create exciting prospects for personalized care. This article provides an overview of the role played by Th1, Th2, Th17, and follicular Th pathways in the most common skin diseases. Additionally, it elucidates the impact of current and upcoming treatments on each of these signaling cascades. Skin diseases predominantly influenced by a single dominant Th pathway such as psoriasis and atopic dermatitis are well-suited for biologics. However, in many other disorders a complex interplay between different immune pathways exists. This can lead to inconsistent efficacy of biologics based on individual patient profiles. In case of activation of several Th pathways, it may be more suitable to consider conventional therapies or JAK inhibitors. Increasing immunological insights have transitioned from laboratory research to practical applications, a trend that is expected to continue growing in the future.</description><identifier>ISSN: 1598-2629</identifier><identifier>EISSN: 2092-6685</identifier><identifier>DOI: 10.4110/in.2024.24.e33</identifier><identifier>PMID: 39513029</identifier><language>eng</language><publisher>Korea (South): 대한면역학회</publisher><subject>Review ; 면역학</subject><ispartof>Immune Network, 2024, 24(5), , pp.1-21</ispartof><rights>Copyright © 2024. The Korean Association of Immunologists.</rights><rights>Copyright © 2024. The Korean Association of Immunologists 2024 The Korean Association of Immunologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2563-863e6e203a15f32d44805776e3d3c8e1b1ce75efa9ba99262070933e377cc403</cites><orcidid>0000-0002-3249-8195 ; 0000-0002-7484-8413 ; 0000-0001-9183-4390 ; 0000-0002-9421-3546 ; 0000-0001-5303-9310</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538609/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538609/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39513029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003135278$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Speeckaert, Reinhart</creatorcontrib><creatorcontrib>Belpaire, Arno</creatorcontrib><creatorcontrib>Lambert, Jo</creatorcontrib><creatorcontrib>Speeckaert, Marijn</creatorcontrib><creatorcontrib>van Geel, Nanja</creatorcontrib><title>Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions</title><title>Immune network</title><addtitle>Immune Netw</addtitle><description>In recent years, there have been significant breakthroughs in the identification of immunological components of skin diseases and in the development of immunomodulatory drugs. Novel therapies create exciting prospects for personalized care. This article provides an overview of the role played by Th1, Th2, Th17, and follicular Th pathways in the most common skin diseases. Additionally, it elucidates the impact of current and upcoming treatments on each of these signaling cascades. Skin diseases predominantly influenced by a single dominant Th pathway such as psoriasis and atopic dermatitis are well-suited for biologics. However, in many other disorders a complex interplay between different immune pathways exists. This can lead to inconsistent efficacy of biologics based on individual patient profiles. In case of activation of several Th pathways, it may be more suitable to consider conventional therapies or JAK inhibitors. Increasing immunological insights have transitioned from laboratory research to practical applications, a trend that is expected to continue growing in the future.</description><subject>Review</subject><subject>면역학</subject><issn>1598-2629</issn><issn>2092-6685</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkc1vEzEQxS0EomnhyhH5goSQNvhj7bW5oKgpJVKhiO6Bm-V4ZxuTrLfYu0X97_E2IQJppJE8v3mep4fQK0rmJaXkvQ9zRlg5zwWcP0EzRjQrpFTiKZpRoVXBJNMn6DSln4TIklfiOTrhWlBOmJ6hH_UGf7PD5rd9SNgHvOq6MUDxBRpvB2jwzTY_Ln3qYwMxfcALfDn6BnDbR3wzxMzceofrCHboIAx4Cc4n34f0Aj1r7S7By0M_Q_Wni_r8c3F1fbk6X1wVjgnJCyU5SGCEWypazpqyVERUlQTecKeArqmDSkBr9dpqnb2QimjOgVeVcyXhZ-jdXjbE1mydN731j_22N9toFt_rlaGTb1rpDH_cw3fjuoPG5YOj3Zm76DsbHx5X_58Ev8lC94ZSwZUkk8Lbg0Lsf42QBtP55GC3swH6MRlOmeKM6VJldL5HXexTitAe_6HETNkZH8yUncmVs8sLr_-97oj_DSsDbw5exzyaEjoyX6-XF5RqoaRi_A9BUaBY</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Speeckaert, Reinhart</creator><creator>Belpaire, Arno</creator><creator>Lambert, Jo</creator><creator>Speeckaert, Marijn</creator><creator>van Geel, Nanja</creator><general>대한면역학회</general><general>The Korean Association of Immunologists</general><scope>DBRKI</scope><scope>TDB</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-3249-8195</orcidid><orcidid>https://orcid.org/0000-0002-7484-8413</orcidid><orcidid>https://orcid.org/0000-0001-9183-4390</orcidid><orcidid>https://orcid.org/0000-0002-9421-3546</orcidid><orcidid>https://orcid.org/0000-0001-5303-9310</orcidid></search><sort><creationdate>202410</creationdate><title>Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions</title><author>Speeckaert, Reinhart ; Belpaire, Arno ; Lambert, Jo ; Speeckaert, Marijn ; van Geel, Nanja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2563-863e6e203a15f32d44805776e3d3c8e1b1ce75efa9ba99262070933e377cc403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Review</topic><topic>면역학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Speeckaert, Reinhart</creatorcontrib><creatorcontrib>Belpaire, Arno</creatorcontrib><creatorcontrib>Lambert, Jo</creatorcontrib><creatorcontrib>Speeckaert, Marijn</creatorcontrib><creatorcontrib>van Geel, Nanja</creatorcontrib><collection>DBPIA - 디비피아</collection><collection>DBPIA (누리미디어)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Immune network</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Speeckaert, Reinhart</au><au>Belpaire, Arno</au><au>Lambert, Jo</au><au>Speeckaert, Marijn</au><au>van Geel, Nanja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions</atitle><jtitle>Immune network</jtitle><addtitle>Immune Netw</addtitle><date>2024-10</date><risdate>2024</risdate><volume>24</volume><issue>5</issue><spage>1</spage><epage>21</epage><pages>1-21</pages><issn>1598-2629</issn><eissn>2092-6685</eissn><abstract>In recent years, there have been significant breakthroughs in the identification of immunological components of skin diseases and in the development of immunomodulatory drugs. Novel therapies create exciting prospects for personalized care. This article provides an overview of the role played by Th1, Th2, Th17, and follicular Th pathways in the most common skin diseases. Additionally, it elucidates the impact of current and upcoming treatments on each of these signaling cascades. Skin diseases predominantly influenced by a single dominant Th pathway such as psoriasis and atopic dermatitis are well-suited for biologics. However, in many other disorders a complex interplay between different immune pathways exists. This can lead to inconsistent efficacy of biologics based on individual patient profiles. In case of activation of several Th pathways, it may be more suitable to consider conventional therapies or JAK inhibitors. Increasing immunological insights have transitioned from laboratory research to practical applications, a trend that is expected to continue growing in the future.</abstract><cop>Korea (South)</cop><pub>대한면역학회</pub><pmid>39513029</pmid><doi>10.4110/in.2024.24.e33</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0002-3249-8195</orcidid><orcidid>https://orcid.org/0000-0002-7484-8413</orcidid><orcidid>https://orcid.org/0000-0001-9183-4390</orcidid><orcidid>https://orcid.org/0000-0002-9421-3546</orcidid><orcidid>https://orcid.org/0000-0001-5303-9310</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1598-2629
ispartof Immune Network, 2024, 24(5), , pp.1-21
issn 1598-2629
2092-6685
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_10643179
source Open Access: PubMed Central
subjects Review
면역학
title Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A02%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nurimedia_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Th%20Pathways%20in%20Immune-Mediated%20Skin%20Disorders:%20A%20Guide%20for%20Strategic%20Treatment%20Decisions&rft.jtitle=Immune%20network&rft.au=Speeckaert,%20Reinhart&rft.date=2024-10&rft.volume=24&rft.issue=5&rft.spage=1&rft.epage=21&rft.pages=1-21&rft.issn=1598-2629&rft.eissn=2092-6685&rft_id=info:doi/10.4110/in.2024.24.e33&rft_dat=%3Cnurimedia_nrf_k%3ENODE11958682%3C/nurimedia_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2563-863e6e203a15f32d44805776e3d3c8e1b1ce75efa9ba99262070933e377cc403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3128322948&rft_id=info:pmid/39513029&rft_nurid=NODE11958682&rfr_iscdi=true